XARELTO 2.5mg Price

Overview

Welcome to Dwaey, specifically on XARELTO 2.5mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Rivaroxaban (micronized).
XARELTO 2.5mg is available in the market in concentration 2.5mg/Tablet and in the form of Tablets/Film-coated.

BAYER PHARMA AG is the producer of XARELTO 2.5mg and it is imported from GERMANY, The most popular alternatives of XARELTO 2.5mg are listed downward .

Mode Of Action

Factor Xa inhibitor that inhibits platelet activation by selectively blocking the active site of factor Xa without requiring a cofactor (eg, antithrombin III) for activity. Blood coagulation cascade is dependent on the activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in the blood coagulation cascade. Dose-dependent inhibition of factor Xa activity observed; antifactor Xa activity is also influenced by rivaroxaban; prolongs PT and aPTT and HepTest .

Indication

• Atrial fibrillation
• Strokes
• Deep venous thrombosis

Precaution

Patient w/ hepatic disease associated w/ coagulopathy, severe HTN, prosthetic heart valve, vascular retinopathy, bronchiectasis. Anaesth w/ post-op indwelling epidural catheter. Hepatic and renal impairment. Pregnancy and lactation. Lactation: Unknown whether distributed in human breast milk; not recommended; a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother

Side Effects

• 1-10% Abdominal pain (<2%)
• Back pain (<4%)
• Blister (1%)
• Bruising (3%)
• Constipation (<3%)
• Diarrhea (<5%)
• Dizziness (<6%)
• Dyspepsia (<2%)
• Epistaxis (4-10%)
• Fatigue (<3%)
• Headache (3-5%)
• Nausea (1-3%)
• Hematuria (<4%)
• Muscle spasm (1%)
• Oropharyngeal pain (<1%)
• Osteoarthritis (<2%)
• Peripheral edema (<6%)
• Pruritus (<2%)
• Pyrexia (1-3%)
• Rash (2%)
• Syncope (<2%)
• Toothache (<1%)
• Urinary tract infection (<1%)
• Vomiting (<2%)
• Wound secretion (<3%) Bleeding Atrial fibrillation (21%; major bleeding 6%) DVT prophylaxis (5-6%; major bleeding <1%) DVT treatment (6-10%; major bleeding 1%) Hematoma (<3%) <1% Agranulocytosis
• Hepatitis
• Dysuria
• Fatal bleeding
• Hematoma
• Hemiparesis
• Hemorrhage
• Hypotension
• Increased amylase
• Increased BUN
• Jaundice
• Menorrhagia
• Retroperitoneal bleeding
• Stevens-Johnson syndrome
• Thrombocytopenia
• Urticaria
• Xerostomia

Contra indication

Patient w/ active pathologic bleeding, significant risk of major bleeding (e.g. recent GI ulcer, oesophageal varices, recent brain, spine, or ophth surgery, recent intracranial haemorrhage, malignant neoplasms, vascular aneurysm).

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks